Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Takehisa Kawata"'
Autor:
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa, Tadao Akizawa
Publikováno v:
PLoS ONE, Vol 17, Iss 2 (2022)
This ad hoc analysis of a previously conducted phase 3 head-to-head comparison study of evocalcet and cinacalcet in secondary hyperparathyroidism patients undergoing maintenance hemodialysis evaluated the efficacy and safety of combined once-daily or
Externí odkaz:
https://doaj.org/article/b610623108cf4b7085485a85c490d358
Autor:
Shin Tokunaga, Takehisa Kawata
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0245785 (2021)
Evocalcet is a novel calcimimetic agent with fewer gastrointestinal (GI) adverse effects compared to cinacalcet. Although it is thought that cinacalcet induces GI side effects through the direct stimulation of the calcium receptor (CaR) expressed in
Externí odkaz:
https://doaj.org/article/8fbbcd8c78904fd9ba6635ffd8fa3559
Autor:
Mariko Sakai, Shin Tokunaga, Mika Kawai, Miki Murai, Misaki Kobayashi, Tetsuya Kitayama, Satoshi Saeki, Takehisa Kawata
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0232428 (2020)
BACKGROUND:Elevated parathyroid hormone (PTH) levels in secondary hyperparathyroidism (SHPT) lead to vascular calcification, which is associated with cardiovascular events and mortality. Increased PTH production is caused by the excessive proliferati
Externí odkaz:
https://doaj.org/article/551a0315a84142f3a8c8a5136ded8c66
Autor:
Takehisa Kawata, Shin Tokunaga, Miki Murai, Nami Masuda, Waka Haruyama, Youji Shoukei, Yutaka Hisada, Tetsuya Yanagida, Hiroshi Miyazaki, Michihito Wada, Tadao Akizawa, Masafumi Fukagawa
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195316 (2018)
Cinacalcet hydrochloride (cinacalcet), an oral calcimimetic agent has been widely used for the management of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD). In sharp contrast to vitamin D receptor activators, cinacalcet suppress
Externí odkaz:
https://doaj.org/article/ac2d2caae5b94be0b3ff292f83e53552
Autor:
Yuichi Endo, Masafumi Fukagawa, Takashi Shigematsu, Takehisa Kawata, Shinji Asada, Tadao Akizawa
Publikováno v:
International Journal of Nephrology and Renovascular Disease
Takashi Shigematsu,1 Shinji Asada,2 Yuichi Endo,3 Takehisa Kawata,2,3 Masafumi Fukagawa,4 Tadao Akizawa5 1Department of Nephrology, Wakayama Medical University, Wakayama, Japan; 2Medical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan; 3R&D D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2b2bfef6ad83100ae240cefaa9c8e3
https://doi.org/10.2147/ijnrd.s243210
https://doi.org/10.2147/ijnrd.s243210
Autor:
Tomoka Hasegawa, Shin Tokunaga, Tomomaya Yamamoto, Mariko Sakai, Hiromi Hongo, Takehisa Kawata, Norio Amizuka
Publikováno v:
Endocrinology. 164(4):bqad022
To elucidate the effect of evocalcet, a new oral calcimimetic to bone of secondary hyperparathyroidism (SHPT) with chronic kidney disease (CKD), the rats were 5/6 nephrectomized and fed on a high-phosphate diet. The treated rats were then divided int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1320cff196f835d023bfa50d47986d4f
http://hdl.handle.net/2115/88922
http://hdl.handle.net/2115/88922
Publikováno v:
Folia Pharmacologica Japonica. 154:35-43
Calcimimetics allosterically activate the calcium receptor (CaR) and inhibit the secretion of parathyroid hormone (PTH). Cinacalcet hydrochloride (cinacalcet) has been approved as the first calcimimetic drug for the treatment of secondary hyperparath
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3483e21ac4b78639a567921c9ab16207
https://doi.org/10.1254/fpj.154.35
https://doi.org/10.1254/fpj.154.35
Autor:
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa, Tadao Akizawa
Publikováno v:
PloS one. 17(2)
This ad hoc analysis of a previously conducted phase 3 head-to-head comparison study of evocalcet and cinacalcet in secondary hyperparathyroidism patients undergoing maintenance hemodialysis evaluated the efficacy and safety of combined once-daily or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::126e8aaa87b4113624f4ffb72fdc2331
https://pubmed.ncbi.nlm.nih.gov/35176038
https://pubmed.ncbi.nlm.nih.gov/35176038
Publikováno v:
Expert review of endocrinologymetabolism. 15(5)
The calcium-sensing receptor is an important treatment target for secondary hyperparathyroidism (SHPT) in patients undergoing dialysis. In addition to vitamin D receptor activator, cinacalcet has recently been widely used for SHPT management, and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a67765baa3fd3f32c94b9485c58071ba
https://pubmed.ncbi.nlm.nih.gov/32552012
https://pubmed.ncbi.nlm.nih.gov/32552012
Calcimimetics represent a class of pharmacological agents that activate the extracellular calcium receptor. The receptor is expressed at high levels in the parathyroid glands, thyroidal C-cells, and the kidney. Calcimimetics can suppress parathyroid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d488abb28d993f0de5438e54226f21ab
https://doi.org/10.1016/b978-0-12-801238-3.11267-x
https://doi.org/10.1016/b978-0-12-801238-3.11267-x
